bioMerieux SA 2024 IR
The report highlights bioMérieux's performance in 2024, achieving sales of €3,980 million with 10.3% organic growth, driven by molecular biology and microbiology ranges. The company advanced its GO•28 strategic plan, focusing on growth, simplification, and corporate social responsibility. Notably, bioMérieux reduced its absolute Scopes 1 and 2 greenhouse gas emissions by 13.3% compared to 2019, exceeding its projections. Additionally, the company completed key acquisitions, including Lumed Inc., to strengthen its software portfolio in the fight against antimicrobial resistance.
Company: bioMerieux SA
Sector: Health Care
Country: France
Year: 2024
Type: IR
Pages: 376
bioMerieux SA
Universal Registration Document
The report highlights bioMérieux's performance in 2024, achieving sales of €3,980 million with 10.3% organic growth, driven by molecular biology and microbiology ranges. The company advanced its GO•28 strategic plan, focusing on growth, simplification, and corporate social responsibility. Notably, bioMérieux reduced its absolute Scopes 1 and 2 greenhouse gas emissions by 13.3% compared to 2019, exceeding its projections. Additionally, the company completed key acquisitions, including Lumed Inc., to strengthen its software portfolio in the fight against antimicrobial resistance.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees